



1806

0360 12/10

PATENT

Atty Dkt 0437-0003.00

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 12 November 1993

11/12/93  
Date

Anna Richard  
Signature

RECEIVED  
NOV 19 1993

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Spitler et al.

Serial No.: 08/105,444

Group Art Unit: Unknown

Filing Date: 11 August 1993

Examiner: Unknown

Title: PROSTATIC CANCER VACCINE

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR 1.97

The Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

The information listed below, which may be material to the examination of the above-identified application, was disclosed to the Examiner at pages 1-4 of the application as originally filed. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of official record in the application. The information includes:

Boring, CC, et al, Cancer Statistics, 1993; CA Cancer J Clin (1993) 43:7-26

Hoover, Jr. HC and Hanna, Jr. MG, Biological Therapy of Cancer (1991) Devita, Jr., DT, et al., Biologic Therapy of Cancer; eds. J.B. Lippincott Co., pgs 670-701

U.S. Patent No. 3,960,827 Filed 1 June 1976

U.S. Patent No. 4,372,945 Filed 8 February 1983

U.S. Patent No. 4,446,122 Filed 1 May 1984  
U.S. Patent No. 4,468,457 Filed 28 August 1984  
U.S. Patent No. 4,689,222 Filed 24 August 1987  
U.S. Patent No. 4,877,611 Filed 31 October 1989  
PCT WO91/11465 Published 9 August 1991  
U.S. Patent No. 5,053,224 Filed 1 October 1991

The references above are summarized on pages 1-4 of the application as originally filed. The summaries contain what the undersigned believes to be the salient aspects of the cited references. They are not intended to be a comprehensive statement of the relevance of the references to the subject invention.

This Information Disclosure Statement is submitted before receipt of the first Office Action on Merits. Therefore, the applicants believe that no fee is due. However, the Commissioner is hereby authorized to charge any fees which may be required by this paper to Deposit Account Number 03-1952.

Applicants would appreciate the Examiner's initialling and returning the Form PTO-1449, indicating that the references have indeed been considered and made of record herein.

This Information Disclosure Statement under 37 CFR 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not

exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

By:

Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

MORRISON & FOERSTER  
2000 Pennsylvania Avenue, N.W.  
Washington, D.C. 20006-1812  
Tel: (202) 887-1500  
Fax: (202) 887-0763